Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Glaxo Wellcome plc

This article was originally published in The Tan Sheet

Executive Summary

Glaxo Wellcome plc: North American Operations Director Phillip Tracy, who oversaw Burroughs Wellcome's role in the Warner Wellcome OTC joint-venture prior to the Glaxo-Wellcome merger, has resigned, effective June 30. Tracy has headed Glaxo Wellcome's OTC business strategy since the merger. The OTC responsibilities move to James Cochrane as part of his oversight of business and commercial development. Two other executive directors also are resigning -- former Wellcome Group Research, Development and Medical Affairs Director David Barry and Group Marketing Director Keith Merrifield...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel